Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Autonomix Medical, Inc.AMIX · Entity 8309 | Director | January 26, 2024 | January 27, 2024 |
| Empery Digital Inc.EMPD · Entity 21 | Director | February 18, 2026 | February 20, 2026 |
| Moleculin Biotech, Inc.MBRX · Entity 7886 | Chief Financial Officer | August 03, 2026 | August 05, 2026 |
| Soliton, Inc.SOLY · Entity 132212 | Director | December 16, 2021 | December 17, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Autonomix Medical, Inc.
Report date January 26, 2024 · Filed January 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 725,000 |
Reported balance
Holding disclosure · report date 2024-01-26 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 725,000 |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2028-10-06 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2024-01-26 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed |
Empery Digital Inc.
Report date February 18, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $993,600.00 · Expires 2034-07-12 | Direct | 0 |
Reported balance
After 2026-02-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-18 · Other · Disposed 2 · Balance 0 F1: Represents the voluntary forfeiture for no value received by the reporting person of options to purchase shares of common stock. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2,232,000.00 · Expires 2033-07-26 | Direct | 0 |
Reported balance
After 2026-02-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-18 · Other · Disposed 1 · Balance 0 F1: Represents the voluntary forfeiture for no value received by the reporting person of options to purchase shares of common stock. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1,440,000.00 · Expires 2031-05-19 | Direct | 0 |
Reported balance
After 2026-02-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-18 · Other · Disposed 1 · Balance 0 F1: Represents the voluntary forfeiture for no value received by the reporting person of options to purchase shares of common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the voluntary forfeiture for no value received by the reporting person of options to purchase shares of common stock.
Moleculin Biotech, Inc.
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 305,673 |
Reported balance
After 2026-08-03 transaction · row 1
1 source rowRow 1 · 2026-08-03 · Purchase · Acquired 293,333 · Balance 305,673 F1: On August 3, 2026, the reporting person acquired 293,333 shares of common stock and Series I warrants to purchase 879,999 shares of common stock at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants in a public offering. |
| Series I WarrantsSEC Table II · derivative / convertible security · Expires 2031-08-03 | Direct | 1,027,717 |
Reported balance
After 2026-08-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-03 · Purchase · Acquired 879,999 · Balance 1,027,717 F1: On August 3, 2026, the reporting person acquired 293,333 shares of common stock and Series I warrants to purchase 879,999 shares of common stock at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants in a public offering. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 3, 2026, the reporting person acquired 293,333 shares of common stock and Series I warrants to purchase 879,999 shares of common stock at a combined purchase price of $0.75 per one share of common stock and three accompanying warrants in a public offering.
Soliton, Inc.
Report date December 16, 2021 · Filed December 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2028-06-19 | Direct | 0 |
Reported balance
After 2021-12-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-12-16 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), immediately prior to the effective time of the merger of Merger Sub with and into the Company (the "Merger"), each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to $22.60 (the "Merger Consideration") minus the exercise price that would be due in cash upon exercise of such option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.62 · Expires 2029-06-27 | Direct | 0 |
Reported balance
After 2021-12-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-12-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), immediately prior to the effective time of the merger of Merger Sub with and into the Company (the "Merger"), each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to $22.60 (the "Merger Consideration") minus the exercise price that would be due in cash upon exercise of such option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.94 · Expires 2030-06-19 | Direct | 0 |
Reported balance
After 2021-12-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-12-16 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), immediately prior to the effective time of the merger of Merger Sub with and into the Company (the "Merger"), each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to $22.60 (the "Merger Consideration") minus the exercise price that would be due in cash upon exercise of such option. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2023-10-19 | Direct | 0 |
Reported balance
After 2021-12-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-12-16 · Disposition to issuer · Disposed 12,500 · Balance 0 F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), immediately prior to the effective time of the merger of Merger Sub with and into the Company (the "Merger"), each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to $22.60 (the "Merger Consideration") minus the exercise price that would be due in cash upon exercise of such option.
F2: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2023 Filed Jun 20, 2023 22:00 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-017885 · rdgdoc.xml · nonDerivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| July 26, 2022 Filed Aug 12, 2022 17:33 UTC | Empery Digital Inc. VLCN · Entity 21 | GrantStock Option · Derivative | 101,250 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001683168-22-005609 · ownership.xml · derivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,250 Underlying: Common stock · 101,250 shares Expires 2032-07-26 Read SEC document |
| July 26, 2022 Filed Mar 16, 2023 16:14 UTC Amendment | Empery Digital Inc. VLCN · Entity 21 | GrantStock Option · Derivative | 101,250 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001683168-23-001538 · ownership.xml · derivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,250 Underlying: Common stock · 101,250 shares Expires 2032-07-26 Read SEC document |
| June 20, 2022 Filed Jun 22, 2022 23:04 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantRestricted Stock Units · Derivative | 162,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-015664 · rdgdoc.xml · derivative · entry 2 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 734,105 Underlying: Common stock · 162,667 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one shares of Company common stock. F2 · price: Issued in connection with the reporting person's employment with the Company. F4 · derivative.exercise_date: The restricted stock units set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. F4 · derivative.expiration_date: The restricted stock units set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. Read SEC document |
| June 20, 2022 Filed Jun 22, 2022 23:04 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 155,000 | Not disclosed Strike: $1.49 | Not disclosed |
DisclosureSEC source: 0001437749-22-015664 · rdgdoc.xml · derivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 571,438 Underlying: Common stock · 155,000 shares Expires 2032-06-20 F2 · price: Issued in connection with the reporting person's employment with the Company. F1 · derivative.exercise_date: The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. Read SEC document |
| June 16, 2022 Filed Jun 22, 2022 00:07 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Exercise / conversionRestricted Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-015535 · rdgdoc.xml · derivative · entry 3 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 416,438 Underlying: Common Stock · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On June 16, 2021, the reporting person was granted 50,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On June 16, 2021, the reporting person was granted 50,000 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| June 16, 2022 Filed Jun 22, 2022 00:07 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Tax withholdingCommon Stock | 3,044 | $1.33 | $4,048.52 |
DisclosureSEC source: 0001437749-22-015535 · rdgdoc.xml · nonDerivative · entry 2 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,123 F2 · shares: Shares withheld for payment of taxes upon vesting of restricted stock unit awards. Read SEC document |
| June 16, 2022 Filed Jun 22, 2022 00:07 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | Exercise / conversionCommon Stock | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-015535 · rdgdoc.xml · nonDerivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 22:07 UTC | Soliton, Inc. SOLY · Entity 132212 | Disposition to issuerWarrant (right to buy) · Derivative | 12,500 | Not disclosed Strike: $1.75 | Not disclosed |
DisclosureSEC source: 0001548187-21-000074 · wf-form4_163977884268775.xml · derivative · entry 4 Foster Jonathan P. · CIK 0001545414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2023-10-19 F2 · price: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the effective time of the Merger, each outstanding and unexercised warrant, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the excess of (i) the number of shares of common stock subject to the warrant, multiplied by the Merger Consideration over (ii) the number of shares of common stock subject to the warrant, multiplied by the per share exercise price of such warrant. Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 22:07 UTC | Soliton, Inc. SOLY · Entity 132212 | Disposition to issuerStock option (right to buy) · Derivative | 15,000 | Not disclosed Strike: $12.94 | Not disclosed |
DisclosureSEC source: 0001548187-21-000074 · wf-form4_163977884268775.xml · derivative · entry 3 Foster Jonathan P. · CIK 0001545414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2030-06-19 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), immediately prior to the effective time of the merger of Merger Sub with and into the Company (the "Merger"), each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to $22.60 (the "Merger Consideration") minus the exercise price that would be due in cash upon exercise of such option. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), immediately prior to the effective time of the merger of Merger Sub with and into the Company (the "Merger"), each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to $22.60 (the "Merger Consideration") minus the exercise price that would be due in cash upon exercise of such option. Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 22:07 UTC | Soliton, Inc. SOLY · Entity 132212 | Disposition to issuerStock option (right to buy) · Derivative | 15,000 | Not disclosed Strike: $14.62 | Not disclosed |
DisclosureSEC source: 0001548187-21-000074 · wf-form4_163977884268775.xml · derivative · entry 2 Foster Jonathan P. · CIK 0001545414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2029-06-27 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), immediately prior to the effective time of the merger of Merger Sub with and into the Company (the "Merger"), each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to $22.60 (the "Merger Consideration") minus the exercise price that would be due in cash upon exercise of such option. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), immediately prior to the effective time of the merger of Merger Sub with and into the Company (the "Merger"), each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to $22.60 (the "Merger Consideration") minus the exercise price that would be due in cash upon exercise of such option. Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 22:07 UTC | Soliton, Inc. SOLY · Entity 132212 | Disposition to issuerStock option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $1.75 | Not disclosed |
DisclosureSEC source: 0001548187-21-000074 · wf-form4_163977884268775.xml · derivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2028-06-19 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), immediately prior to the effective time of the merger of Merger Sub with and into the Company (the "Merger"), each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to $22.60 (the "Merger Consideration") minus the exercise price that would be due in cash upon exercise of such option. F1 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), immediately prior to the effective time of the merger of Merger Sub with and into the Company (the "Merger"), each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to $22.60 (the "Merger Consideration") minus the exercise price that would be due in cash upon exercise of such option. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:21 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantRestricted Stock Units · Derivative | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-015276 · rdgdoc.xml · derivative · entry 2 Foster Jonathan P. · CIK 0001545414 · Exec. Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 428,938 Underlying: Common Stock · 50,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Company common stock. F2 · price: Issued in connection with the reporting person's employment with the Company. F4 · derivative.exercise_date: The restricted stock units set forth in this table vest in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. F4 · derivative.expiration_date: The restricted stock units set forth in this table vest in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 20:21 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 108,770 | Not disclosed Strike: $3.73 | Not disclosed |
DisclosureSEC source: 0001437749-21-015276 · rdgdoc.xml · derivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Exec. Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 378,938 Underlying: Common Stock · 108,770 shares Expires 2031-06-16 F2 · price: Issued in connection with the reporting person's employment with the Company. F1 · derivative.exercise_date: The options set forth in this table vest in four equal annual installments, beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. Read SEC document |
| July 02, 2020 Filed Jul 7, 2020 21:14 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 460,000 | Not disclosed Strike: $0.93 | Not disclosed |
DisclosureSEC source: 0001659617-20-000172 · wf-form4_159415646381168.xml · derivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Exec. Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,621,000 Underlying: Common Stock · 460,000 shares Expires 2030-07-02 F2 · price: (2) Issued in connection with the reporting person's employment with the Company. F1 · derivative.exercise_date: (1) The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. Read SEC document |
| June 19, 2020 Filed Jun 23, 2020 13:20 UTC | Soliton, Inc. SOLY · Entity 132212 | GrantStock option (right to buy) · Derivative | 15,000 | Not disclosed Strike: $12.94 | Not disclosed |
DisclosureSEC source: 0001548187-20-000066 · wf-form4_159291844147774.xml · derivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,500 Underlying: Common Stock · 15,000 shares Expires 2030-06-19 F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company. F1 · derivative.exercise_date: The options set forth in this table vest one year after issuance, subject to the grantee's continued service on the Company's Board of Directors. Read SEC document |
| July 11, 2019 Filed Jul 15, 2019 20:04 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 315,000 | Not disclosed Strike: $1.31 | Not disclosed |
DisclosureSEC source: 0001659617-19-000101 · wf-form4_156322106686428.xml · derivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Exec. Vice President and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,161,000 Underlying: Common Stock · 315,000 shares Expires 2029-07-11 F2 · price: (2) Issued in connection with the reporting person's employment with the Company. F1 · derivative.exercise_date: (1) The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 20:31 UTC | Soliton, Inc. SOLY · Entity 132212 | GrantStock option (right to buy) · Derivative | 15,000 | Not disclosed Strike: $14.62 | Not disclosed |
DisclosureSEC source: 0001437749-19-013232 · rdgdoc.xml · derivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,500 Underlying: Common Stock · 15,000 shares Expires 2029-06-27 F2 · price: The options were issued in connection with the reporting person's Board of Director service to the Company. F1 · derivative.exercise_date: The options set forth in this table vest one year after issuance, subject to the grantee's continued service on the Company's Board of Directors. Read SEC document |
| June 06, 2018 Filed Jun 8, 2018 21:24 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 301,000 | Not disclosed Strike: $1.82 | Not disclosed |
DisclosureSEC source: 0001144204-18-033606 · tv496090_4.xml · derivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 846,000 Underlying: Common stock · 301,000 shares Expires 2028-06-06 F2 · price: Issued in connection with the reporting person's employment with the Company. F1 · derivative.exercise_date: The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. Read SEC document |
| October 03, 2017 Filed Oct 5, 2017 22:02 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | GrantStock option (right to buy) · Derivative | 145,000 | Not disclosed Strike: $2.49 | Not disclosed |
DisclosureSEC source: 0001144204-17-051545 · v476493_4.xml · derivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 545,000 Underlying: Common stock · 145,000 shares Expires 2027-10-03 F2 · price: Issued in connection with the reporting person's employment with the Company. F1 · derivative.exercise_date: The stock option set forth in this table vests in four equal annual installments beginning on the first anniversary of the Transaction Date, subject to the grantee's continued service to the Company on each vesting date. Read SEC document |
| April 25, 2017 Filed Apr 26, 2017 20:30 UTC | Moleculin Biotech, Inc. MBRX · Entity 7886 | PurchaseCommon Stock | 10,000 | $0.86 | $8,649.00 |
DisclosureSEC source: 0001144204-17-022289 · v465197_form4.xml · nonDerivative · entry 1 Foster Jonathan P. · CIK 0001545414 · Exec. Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.